Work

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

Year: 2020

Type: article

Study design: Case Report

Abstract: Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15-77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%.

Source: Infection

DOI: 10.1007/s15010-020-01475-8

Authors: A. T. Coste, A. Kritikos, J. Li, N. Khanna, D. Goldenberger, C. Garzoni, C. Zehnder, K. Boggian, D. Neofytos, A. Riat, D. Bachmann, D. Sanglard, F. Lamoth, The Fungal Infection Network of Switzerland (FUNGINOS), F. Lamoth, N. Khanna, K. Boggian, D. Sanglard

Institutions: Centre Hospitalier Universitaire Vaudois, University of Lausanne, University of Basel, University Hospital of Basel, Clinica Luganese Moncucco, Kantonsspital St. Gallen, University Hospital of Geneva

Language: English

Topic: Antifungal resistance and susceptibility

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,760

Funder: Université de Lausanne

OpenAlex ID: W3043323594

FWCI: 1.373

Cites: 13

Cited by: 74

Related to: 10